Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07116057 · ClinicalTrials.gov registry record · Phase 1

MOv19-BBz CAR T Cells in FRa+ Cancers

A Phase 1 study of Recurrent Lung Non-Small Cell Carcinoma and Metastatic Non Small Cell Lung Cancer, sponsored by University of Pennsylvania.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT07116057 is a Phase 1 study of Recurrent Lung Non-Small Cell Carcinoma and Metastatic Non Small Cell Lung Cancer that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 10 participants, below the 119-participant average among 30 other Recurrent Lung Non-Small Cell Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07116057, a Phase 1 study of Recurrent Lung Non-Small Cell Carcinoma and Metastatic Non Small Cell Lung Cancer, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only. Subjects will receive a single dose of MOv19-BBz CAR T cells via intrapleural infusion following lymphodepleting chemotherapy. Subjects without an existing intra-pleural catheter will have a temporary pleural catheter placed for the study. Subjects may initiate treatment with commercial checkpoint inhibitors per routine care beginning at least 28 days after receiving MOv19-BBz CAR T cells.

Conditions Studied

Recurrent Lung Non-Small Cell Carcinoma Metastatic Non Small Cell Lung Cancer

Interventions

  • BIOLOGICAL MOv19-BBz CAR T cells
  • DRUG Cyclophosphamide/Fludarabine
  • DEVICE FRa Expression Testing

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-10-07
Est. Completion 2040-10
Phase Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07116057

The ClinicalTrials.gov registry entry for NCT07116057 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 30 other Recurrent Lung Non-Small Cell Carcinoma trials with a reported enrollment target (92% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Recurrent Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which MOv19-BBz CAR T cells is the first listed.

NCT07116057 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT07116057 about?

NCT07116057 is a clinical study titled "MOv19-BBz CAR T Cells in FRa+ Cancers". This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers. This study will be initiated in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) only...

What is the current status of trial NCT07116057?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-10-07. Estimated completion is 2040-10.

What conditions does trial NCT07116057 study?

This clinical trial studies the following conditions: Recurrent Lung Non-Small Cell Carcinoma, Metastatic Non Small Cell Lung Cancer.

What interventions are being tested in trial NCT07116057?

The interventions under investigation include: MOv19-BBz CAR T cells (BIOLOGICAL), Cyclophosphamide/Fludarabine (DRUG), FRa Expression Testing (DEVICE).

Who is sponsoring clinical trial NCT07116057?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07116057 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Lung Non-Small Cell Carcinoma

All registered trials for this condition

Metastatic Non Small Cell Lung Cancer

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.